Aduhelm

Pic:getty/andrewbrookes

Biogen releases long-term Aduhelm data

By Rachel Arthur

Biogen has announced new Phase 3 data showing that, after nearly 2.5 years of treatment, Aduhelm continued to reduce two key Alzheimer’s disease pathologies.

Pic:getty/andrewbrookes

Biogen halves price of Aduhelm in the US

By Rachel Arthur

As of January 1, 2022, Biogen will cut the price of its Alzheimer’s drug Aduhelm (aducanumab-avwa) in half: saying too many patients are not currently being offered the choice of the drug due to financial considerations.

© GettyImages/DNY59

FDA lead calls for independent inquiry into Biogen drug approval

By Jane Byrne

Acting US FDA commissioner, Janet Woodcock, has called for an independent federal review of interactions between officials at her agency and representatives of Biogen, prior to the recent approval of the pharma company’s treatment for Alzheimer’s disease....